New Market Research Report: Mersana Therapeutics, Inc. - Product Pipeline Review - 2013

New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

Logo

Boston, MA -- (SBWire) -- 08/06/2013 --Global Market Direct's pharmaceuticals report, "Mersana Therapeutics, Inc. - Product Pipeline Review - 2013" provides data on the Mersana Therapeutics, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Mersana Therapeutics, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from Mersana Therapeutics, Inc. and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Mersana Therapeutics, Inc. - Brief Mersana Therapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Mersana Therapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Mersana Therapeutics, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Mersana Therapeutics, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

View Full Report Details and Table of Contents

Reasons to Get This Report

- Evaluate Mersana Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Mersana Therapeutics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Mersana Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Mersana Therapeutics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Mersana Therapeutics, Inc. and identify potential opportunities in those areas.

Companies Mentioned in this Report: Mersana Therapeutics, Inc.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Mersana Therapeutics, Inc. - Product Pipeline Review - 2012
- Nektar Therapeutics - Product Pipeline Review - 2013
- Addex Therapeutics - Product Pipeline Review - 2013
- United Therapeutics Corporation - Product Pipeline Review - 2013
- Sarepta Therapeutics, Inc. - Product Pipeline Review - 2013
- Advinus Therapeutics Ltd. - Product Pipeline Review - 2013
- Chroma Therapeutics Ltd. - Product Pipeline Review - 2013
- Onconova Therapeutics, Inc - Product Pipeline Review - 2013
- Inflammatory Bowel Disease - Pipeline Review, H1 2013
- Pain Therapeutics, Inc. - Product Pipeline Review - 2013

Media Relations Contact

Bill Thompson
Director of Marketing
800-844-8156
http://www.fastmr.com

View this press release online at: http://rwire.com/294660